NEW YORK (GenomeWeb News) – Affymetrix today said that it has expanded its license agreement with Siemens Healthcare Diagnostics for its branched DNA (bDNA) technology.

The Santa Clara, Calif.-based firm now has exclusive rights to develop and sell in situ QuantiGene ViewRNA products in the in vitro diagnostic market. The products are currently for research-use only. The license also provides Affy exclusive rights to alkaline phosphatase conjugated oligonucleotides and the use of them in bDNA methods for in situ detection using Fast Red substrates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.